Search

Displaying results 3711 - 3720 of 7503 in total
  1. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents. … The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine.

  2. Drug

    Selamectin

    go.drugbank.com/drugs/DB11459
    ExperimentalVet approved

    It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin. Selamectin is not approved for human use. … Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well

  3. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. … Results published from the CLL clinical trial failed to meet primary endpoints.

  4. Drug

    Carteolol

    go.drugbank.com/drugs/DB00521
    Approved

    A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

    Categories: Beta Blocking Agents, Non-Selective
  5. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

    Categories: Analgesics, Non-Narcotic
  6. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported. … An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies.

  7. Drug

    Human Menstrual Blood-derived Stem Cells

    go.drugbank.com/drugs/DB15738
    Investigational

    ESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted differentiation potency but also a lack of tumorigenicity. … Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind.

  8. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    [A214475] Early _in vitro_ studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. … [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.

    Synonyms: INO-4800 DNA Coronavirus Vaccine
  9. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608].

  10. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.